Under the agreement, Gallus is acquiring several Xcellerex bioproduction systems for new suites and laboratories at its existing manufacturing facility.

The strategic collaboration will provide Gallus with expanded cGMP biomanufacturing capacity by leveraging the key advantages of the turnkey Xcellerex FlexFactory GMP manufacturing platform suite.

Gallus is acquiring small scale 10L bioreactors for its expanded development laboratory and a turnkey FlexFactory cGMP manufacturing line with XDR single?use bioreactors up to 2000 liter scale for clinical supply.

Mark Bamforth, president and CEO of Gallus, said: “The partnership with Xcellerex allows us to leverage their single use biomanufacturing platform. The first manufacturing suite will be in place by the end of 2011. Additional suites can be added to meet specific customer needs, within the existing facility at our site in St. Louis.”

In addition this partnership will provide Xcellerex’s customers unprecedented access to a commercial, FDA approved, biomanufacturing facility.

In August 2010, Xcellerex has signed a memorandum of understanding with SK Chemicals for an alliance to develop and commercialize SK-developed vaccines with Xcellerex’s FlexFactory biomanufacturing platform.

Gallus is a contract biologics manufacturer that was established in 2010 and recently acquired an existing Johnson & Johnson/Centocor manufacturing facility in St. Louis, Missouri.

Will the collaboration benefit the firms?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.